Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Immunotherapy
|
February 28, 2025
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe
Tomoko Hasunuma, Clive Grattan, Takashi Eto, et al.
The New England Journal of Medicine
|
February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
The New England Journal of Medicine
|
March 5, 2025
Remibrutinib in Chronic Spontaneous Urticaria
Martin Metz, Ana Giménez-Arnau, Michihiro Hide, et al.
The World Allergy Organization Journal
|
January 4, 2013
Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
Mario Sánchez-Borges, Riccardo Asero, Ignacio J Ansotegui, et al.
The Journal of Allergy and Clinical Immunology
|
October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
Allergy
|
December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria
Ana M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
The Journal of Allergy and Clinical Immunology
|
October 12, 2022
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
Jonathan Corren, David Larson, Matthew C Altman, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials
Ana Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Lancet (London, England)
|
November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Marcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Immunotherapy
|
February 28, 2025
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe
Tomoko Hasunuma, Clive Grattan, Takashi Eto, et al.
The New England Journal of Medicine
|
February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
The New England Journal of Medicine
|
March 5, 2025
Remibrutinib in Chronic Spontaneous Urticaria
Martin Metz, Ana Giménez-Arnau, Michihiro Hide, et al.
The World Allergy Organization Journal
|
January 4, 2013
Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
Mario Sánchez-Borges, Riccardo Asero, Ignacio J Ansotegui, et al.
The Journal of Allergy and Clinical Immunology
|
October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
Allergy
|
December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria
Ana M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
The Journal of Allergy and Clinical Immunology
|
October 12, 2022
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
Jonathan Corren, David Larson, Matthew C Altman, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials
Ana Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Lancet (London, England)
|
November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Marcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Page
of 2